| HOME >> BIOLOGY >> TECHNOLOGY |
NEW YORK, Sept. 4, 2012 /PRNewswire/ -- Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes, today announced that the company has named Richard A. Franco, Sr. to its Board of Directors.
Richard A. Franco is the President of the Richard's Group, Ltd., a healthcare advisory firm and cofounder of LipoScience, Inc. He has over 35 years of executive and leadership experience in the healthcare industry. Since January 2009, Mr. Franco had served as Chairman, President and Chief Executive Officer of DARA Pharmaceuticals, Inc. Prior to that, he served in several senior executive capacities at Glaxo, Inc., DARA, LipoScience, Inc., Trimeris Inc. with over 16 years with Eli Lilly and Company. He is currently on the boards of Metropolitan Health Networks, Inc., and Research Triangle Chapter of the National Association of Corporate Directors (NACD) and served on the boards of Salix Pharmaceuticals, as well as TriPath Imaging, Inc., NeoMatrix, Inc., Tranzyme, Inc., EntreMed, Inc., Amarillo Biosciences, and the Wake County United Way. He received a B.S. in Pharmacy from St. John's University and has completed executive programs at the Wharton School of the University of Pennsylvania, Duke University Fuqua School of Business, the School of Business at the University of Michigan, Tuck School of Business at Dartmouth College and the Kellogg School of Management at Northwestern University.
"Richard brings a distinguished career and important skill sets to our Board of Directors and we welcome his insights as we mature as a public company," said John Steel, Chairman and CEO of Islet Sciences. "Richard's significant experience and success both operationally and as a Director is a perfect fit for our company as Islet Sciences works toward a new treatment modality for diabetes. We look forward to Richard's counsel
'/>"/>
| SOURCE Islet Sciences, Inc. Copyright©2012 PR Newswire. All rights reserved |